scholarly journals Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease

2021 ◽  
Author(s):  
Karamat Hussain Shah Bukhari ◽  
Asma Asghar ◽  
Najma Perveen ◽  
Arshad Hayat ◽  
Sermad Ahmad Mangat ◽  
...  
Keyword(s):  
Side Effects ◽  
Standard Of Care ◽  
Viral Clearance ◽  
Secondary Outcome ◽  
Military Hospital ◽  
Laboratory Parameters ◽  
Function Tests ◽  
Moderate Disease ◽  
Group A ◽  
Group B

AbstractObjectiveTo evaluate the efficacy of ivermectin (IVM) as an addition to the standard of care (SOC) treatment in COVID-19 patients with mild and moderate diseaseMaterials and MethodsA randomized clinical trial (Trial registration # NCT04392713) was carried out at Combined Military Hospital Lahore from March 15, 2020, to June 15, 2020. Eighty-six patients with reverse transcriptase-polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection completed the trial protocol. Patients were stratified via the lottery method into two groups. Group A was administered standard of care (SOC) treatment as per existing hospital guidelines whereas group B was given ivermectin (single dose of 12 milligrams) along with SOC treatment. PCR was repeated at 72 hours, 7th day, and at 14th day of admission for both the groups and the point at which the PCR became negative was noted. Complete blood counts, liver function tests and renal function tests were done at recruitment, 7th day, and 14th day. The primary outcome was the viral clearance, measured as days to achieve PCR negativity. The secondary outcome was the development of any adverse side effects pertinent to ivermectin or derangement in baseline laboratory parameters.ResultsIn group A, 36 (80%) participants were males, and 9 (20%) were females, whereas in group B, 37 (90.2%) were males and 4 (9.8%) were females. Mean age was 39.0± 12.6 and 42.2 ± 12.0 years for groups A and B, respectively (p= 0.394). There was early viral clearance in group B as compared to group A (p=0.001). No adverse reaction or derangements in laboratory parameters was noted in the intervention arm during the trial period.ConclusionIn the intervention arm, early viral clearance was observed and no side effects were documented. Therefore ivermectin is a potential addition to the standard care of treatment in COVID-19 patients.

Miami NICE trial: Nutritional support for patients incurring chemotherapy side effects.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6568-6568
Author(s):  
Damien Mikael Hansra ◽  
Catherine Diaz ◽  
Skip Camp ◽  
Caroline Randolph ◽  
Christine Norman-Tiner ◽  
...  
Keyword(s):  
Weight Gain ◽  
Side Effects ◽  
Systemic Chemotherapy ◽  
Standard Of Care ◽  
Mitigation Strategies ◽  
Initial Assessment ◽  
Dietary Counseling ◽  
Secondary Endpoints ◽  
Group A ◽  
Group B

6568 Background: Few studies have been performed addressing nutritional interventions & mitigation strategies to address side effects such as weight gain, anorexia, dysgeusia, in patients (pts) undergoing chemotherapy. We aim to study the effect of nutritional counseling on body mass index (BMI) and other side effects in pts undergoing systemic chemotherapy. Methods: Prospective randomized study of 50 pts into two groups (A & B). Group A was randomized to standard of care: oncologist visits once per month x 3 months, routine physician counseling & dietary recommendations. Group B: standard of care + nutritionist intervention which included 3 visits x 30 mins each. Nutritionists performed an initial assessment of pts at the first session (template provided in poster) then tailored dietary counseling monthly x3 months which includes dietary strategies to mitigate side effects, pt & caregiver education, recipes, & handouts (provided in poster). Inclusions: medically insured male & female adults with active malignancies (hematologic &boncologic) on chemotherapy (neoajuvant, adjuvant, palliative). Exclusions: pts with head & neck, stomach, esophagus, pancreatic tumors & pts with pre-existing cachexia. Data collected: pt gender, age, race, ethnicity, cancer subtype, TNM staging, chemotherapy regimen. Primary objective: compare change in BMI at visit 1, 2, &3. Secondary endpoints: anorexia, nausea, vomiting, depression, etc. reported in poster. Mean change in BMI, secondary endpoints compared using students T-test with ANOVA using SAS software version 8.0 & minitab version 17. Results: Group A initial BMI = 28.85 vs group B initial BMI = 27.34 (p = 0.05). Change in BMI group A vs B at visit 1 (0.4 vs 0.09, p = 0.002), visit 2 (4.6 vs -0.52, p = 0.001), visit 3 (6.5 vs 0.46, p = 0.003). Demographics & secondary endpoints reported in poster. Conclusions: We found dietary counseling in addition to standard of care was associated with significant mitigation of weight gain in patients on systemic chemotherapy. Dietary counseling is a relatively simple, inexpensive, individualized, & reproducible method to mitigate chemotherapy related weight gain.

scholarly journals OPEN CHOLECYSTECTOMY

2010 ◽  
Vol 17 (02) ◽  
pp. 193-198
Author(s):  
ALI KASHIF ◽  
FAHEEM FEROZE ◽  
WAQAS AHMAD KAZI
Keyword(s):  
Side Effects ◽  
Rescue Medication ◽  
Open Cholecystectomy ◽  
Postoperative Nausea And Vomiting ◽  
Study Drug ◽  
Military Hospital ◽  
Induction Agent ◽  
Group A ◽  
Group B ◽  
Anaesthesia Care

Background: Postoperative nausea and vomiting (PONV) are most common and distressing complications after anaesthesia and surgery, leading to various problems. Metoclopramide, a benzamide, used as an anti-emetic, has got various side-effects. Propofol, a short acting induction agent, possesses anti-emetic properties in sub hypnotic doses, without having unwanted side- effects in this low dose. Objectives: To compare the frequency of PONV in patients treated with propofol and metoclopramide. Study Design: Experimental study. Setting: Department of anaesthesia and intensive care, Combined Military Hospital Rawalpindi. Duration: 06 months (01st July to 31st December 2004). Materials and Methods: 182 female patients scheduled for open cholecystectomy were selected for this study. All of them received general anaesthesia without any prophylactic antiemetic. Out of them, 60 patients who complained of PONV in post anaesthesia care unit (PACU) were selected by non probability convenience sampling and were equally divided into two groups. Group ‘A’ received propofol (0.5 mg/kg) while group ‘B’ received metoclopramide (0.2 mg/kg). Recurrence of PONV was recorded 60 min after administration of the study drug. Patients still complaining of PONV 30 min after administration of the study drug received a rescue medication i.e. I/V ondansetron (4mg). Results: In group “A”,18 patients responded to intervention (60%) whereas 26 (86.66%) patients gave a positive response in group “B” (p 0.020). More patients who received propofol needed the rescue medication (40%) than those who received metoclopramide (13.33%) (p 0.020). Conclusion: Metoclopramide is a better option for managing PONV than propofol. 

scholarly journals Lorazepam As Anxiolytic Sedative Night Before Operation

2012 ◽  
Vol 7 (2) ◽  
pp. 25-28
Author(s):  
ME Karim ◽  
MH Rahman ◽  
MHMD Hossain ◽  
MN Ahsan
Keyword(s):  
Body Weight ◽  
Side Effects ◽  
Military Hospital ◽  
Male Population ◽  
Female Population ◽  
Haemodynamic Parameters ◽  
Elective Surgical Procedures ◽  
Group A ◽  
Group B ◽  
Induction Of Anaesthesia

Introduction: Surgical patients have a high incidence of anxiety and there is a significant inverse relationship between anxiety and smoothness in induction of anaesthesia. The benzodiazepines are very effective at melting away the active terror of anxiety. Diazepam, a long acting benzodiazepine, is widely used by the anaesthesiologist to allay anxiety and provide sedation. The metabolism of diazepam is slow and is depressed by many factors such as old age, disease states (e.g. hepatic cirrhosis) and concomitant drug administration (e.g. cimetidine). Lorazepam, an intermediate acting benzodiazepine, is well absorbed orally. It is conjugated in the liver to the pharmacologically inactive glucuronide and its metabolism is less impaired by the above factors. Objective: To compare the anxiolytic properties of lorazepam with diazepam before elective surgical procedures. Method: One hundred patients of American Society of Anaesthesiologists (ASA) grade I and grade II, who were scheduled for general surgical, gynaecological operative procedures under general and regional anaesthesia in Combined Military Hospital, Saidpur Cantonment, during the period between June 2008 to June 2010, were included in this study. They were randomly distributed into two groups. Subjects of group A (n=50) received diazepam (Sedil) orally in a dose of 5 mg for <30 kg body weight or 10 mg for 30-70 kg body weight or 15 mg for >70 kg body weight. Subjects of group B (n=50) received lorazepam (Ativan) orally in a dose of 2 mg for <30 kg body weight or 4 mg for 30-70 kg body weight or 6 mg for >70 kg body weight. The effects of the two drugs as anxiolytic sedatives were compared on the basis of haemodynamic parameters, side effects and quality of sleep. Results: There was no significant change in haemodynamic parameters between the two groups. Drugs on group B (Lorazepam group) were found to be more anxiolytic than drugs on group A (Diazepam group). Twenty percent of patients in diazepam group complained of moderate anxiety but it was absent in lorazepam group (p<0.01). Six percent of patients were restless/agitated in preoperative period in diazepam group, but it was absent in lorazepam group. Percentage of tranquil patients was significantly higher in lorazepam group (44%) than that in diazepam group (30%). Hangover effect was noted markedly in group B patients (44%) which was nil in group A patients (p<0.01), but it was beneficial for induction of anaesthesia. Moreover this hangover effect was significantly higher (p<0.01) in female population (50%) than in male population (21.05%). Some other side effects like nausea, vertigo were also noticed in patients of both groups and females were more susceptible to these side effects than males which might be an individual variation. Conclusion: Considering all the factors, lorazepam appeared to be a better option than diazepam as anxiolytic sedative night before operation. DOI: http://dx.doi.org/10.3329/jafmc.v7i2.10392 JAFMC 2011; 7(2): 25-28

scholarly journals Randomized control trial to compare the effectiveness of mifepristone followed by misoprostol at 12 hours interval versus misoprostol alone in second trimester medical termination of pregnancy

2018 ◽  
Vol 7 (8) ◽  
pp. 3299
Author(s):  
Preet Kamal Bedi ◽  
Arunima Saini
Keyword(s):  
Side Effects ◽  
Cervical Dilatation ◽  
Secondary Outcome ◽  
Second Trimester ◽  
Trimester Abortion ◽  
Medical College ◽  
Significant Difference ◽  
Group A ◽  
The Mean ◽  
Group B

Background: Mifepristone priming in second trimester abortions not only decreases the induction-abortion interval (IAI) but also lessens the total misoprostol dose required and hence reduces adverse effects. The present study aims to compare the role of mifepristone priming 12 hours before misoprostol administration so as to increase patient compliance and shorten the duration of hospital stay.Methods: This prospective study was conducted over a period of one year, on 50 patients requiring second trimester abortion, at Department of Obstetrics and Gynaecology, Government Medical College, Amritsar. The patients were divided into two groups with 1:1 randomization. In Group A, 25 women were given tablet mifepristone 200 mg orally followed 12 hours later by tablet misoprostol 400 µg per vaginum followed by the same dose 3 hourly for a maximum of five doses per 24 hours. In group B, 25 women received only tablet misoprostol 400 µg vaginally in the posterior fornix followed by the same dose 3 hourly for a maximum of five doses per 24 hours. Primary outcome was to compare the completeness of expulsion of products of conception by pelvic ultrasound after 48 hours of the last dose administered. Secondary outcome was to compare the Induction abortion interval (IAI), mean dose of misoprostol required, side effects, effect of parity, gestational age and cervical dilatation on IAI with both the regimens used.Results: The success rate was 76% in group A and 64% in group B. The mean induction abortion interval in group A was 8.9±4.70 hours whereas in group B, it was 13.14±6.03 hours and this difference was statistically significant (p = 0.008). A statistically significant difference was also observed in mean dose of misoprostol required in group A and B being 1232.00±398.60 µg and 1584.00±423.94 µg respectively (p=0.004). The side effects were less in group A. Parity and cervical dilatation hold an inverse relation with the mean IAI whereas it has a direct relation with the gestational age.Conclusions: Regimen involving mifepristone priming 12 hours before misoprostol is better than misoprostol alone regimen with significant reduction in IAI, mean dose of misoprostol and less side effects. 

scholarly journals Co-relation between high resolution computerised tomography (HRCT) score and effectiveness of remdesivir treatment in covid-19 positive pregnant patients

2021 ◽  
Vol 7 (4) ◽  
pp. 200-204
Author(s):  
Pratibha Baldawa ◽  
Sachin Baldawa ◽  
Hafeez Junaidi
Keyword(s):  
Side Effects ◽  
Hospital Stay ◽  
Death Rate ◽  
Respiratory Illness ◽  
Secondary Outcome ◽  
Rapid Decline ◽  
Icu Admission ◽  
Group A ◽  
Group B ◽  
Time Of Admission

To evaluate the effectiveness of Remdesivir in COVID-19 POSITIVE PREGNANT patients & its co-relation with their HRCT score (with abdominal lead shield) at the time of admission at our institute. It was a retrospective observational study including 93 COVID -19 POSITIVE pregnant patients at varied weeks of gestation admitted and treated at our institute from March 2020 till June 2021. Out of these 15 patients required INTENSIVE CARE UNIT (ICU) admission due to their disease severity and received Remdesivir after physician consultation. Remaining 78 patients had HRCT SCORE of 7 or less (MILD CATEGORY) and did not require ICU admission and hence were excluded from receiving remdesivir.They were divided into 2 groups – Group A and Group B. Group A (MODERATE CATEGORY) including covid -19 positive pregnant patients with HRCT score of 8 to &#60;17/25 had 8 patients and Group B (SEVERE CATEGORY) including covid -19 positive pregnant patients with high HRCT Score of &#62;17/25 had 7 patients. The primary outcome was to evaluate difference in both groups for clinical improvement after 5 days of initiation of Remdisivir therapy in terms of (a) Oxygen requirement (b) Spo2 levels (c) length of hospital stay (d) Death rate (e) HRCT score on day 10 after initiation of remdesivir therapy. Secondary outcome was to evaluate side effects of the drug on the mother and its effect on the baby while in-utero and after delivery. Covid-19 positive pregnant patients with HRCT Score of 8 to &#60;17/25(Group A) showed good prognosis & recovery with rapid decline in Oxygen requirements & improving Spo2 levels after initiation of Remdesivir. They had significantly lower duration of hospital stay (Mean stay of 10.4 + 2.1 days, p &#60; 0.05) and significantly lower death rates (0%, p &#60; 0.05) compared to Group B. Whereas covid -19 positive pregnant patients with high HRCT Score of &#62;17/25 (Group B) did not respond even to prolonged Remdesivir therapy (10 days) and had significantly longer hospital stay (26 + 5.6 days, p &#60;0.05) with significantly higher death rate (42.86% , p&#60;0.05). Patients tolerated Remdesivir well without any side effects. Patients delivered healthy babies with no signs of respiratory illness or any untoward side effects on the baby due to use of Remdesivir. Early referral of COVID -19 positive pregnant patient to hospital when lung lesions are still mild to moderate can be effectively treated with Remdesivir. But severe Covid -19 infection in pregnancy with rampant and excessive ground glass opacities on HRCT at the time of admission is difficult to treat and may not respond to Remdesivir therapy.

scholarly journals ACUTE RENAL COLIC

2010 ◽  
Vol 17 (01) ◽  
pp. 59-63
Author(s):  
MUHAMMAD ALI NAQVI ◽  
Zl MIRZA
Keyword(s):  
Emergency Department ◽  
Side Effects ◽  
Pain Relief ◽  
Diclofenac Sodium ◽  
Military Hospital ◽  
Rescue Analgesia ◽  
Quasi Experimental ◽  
Group A ◽  
Ureteric Colic ◽  
Group B

Objective: To compare the efficacy of Nelbuphine hydrochloride (opioid) and Diclofenac Sodium (NSAID) in management of Acuterenal pain. Design: Prospective non-randomized quasi experimental study. Setting: This study was conducted in Emergency department (ED)of Combined Military Hospital, Lahore. Period: From 1st April 2008 to 31 July 2009. Patients and Method: A Total of 100 patients presentingin emergency department with a clinical diagnosis of renal and Ureteric colic were studied. They were randomly divided in to equal andcomparable groups, Group A & B. Severity of pain was assessed using a Visual Analogue scale (VAS). Group A was treated with IntravenousNelbuphine 10mg and group B was given intramuscular Diclofenac Sodium 75mg. Assessment of Pain relief, both onset and complete responsewas assessed in both groups. In addition to the pain relief, side effects like Nausea, vomiting, respiratory depression, drowsiness and injectionsite pain were also assessed. Results: Nelbuphine was found significantly superior (p=0.05) to Diclofenac, both for time of onset of pain reliefand complete pain relief. Moreover less patients required rescue analgesia in Group A (p=0.05). Only one patient treated with Group A hadrespiratory depression which was statistically insignificant (p=0.05). There was a 3.5% increase in Nausea and vomiting in Nelbuphine treatedpatients. Conclusion: Nelbuphine is a safe and rapid acting Opioid with few side effects. It should be preferred over Diclofenac sodium intreatment of Acute Renal pain.

scholarly journals Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yong Hoon Kim ◽  
Ae-Young Her ◽  
Myung Ho Jeong ◽  
Byeong-Keuk Kim ◽  
Sung-Jin Hong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Outcomes ◽  
Secondary Outcome ◽  
Drug Eluting Stent ◽  
Diabetes Group ◽  
Repeat Revascularization ◽  
Group A ◽  
Group B ◽  
Diabetes Patients

AbstractWe investigated the effects of stent generation on 2-year clinical outcomes between prediabetes and diabetes patients after acute myocardial infarction (AMI). A total of 13,895 AMI patients were classified into normoglycemia (group A: 3673), prediabetes (group B: 5205), and diabetes (group C: 5017). Thereafter, all three groups were further divided into first-generation (1G)-drug-eluting stent (DES) and second-generation (2G)-DES groups. Patient-oriented composite outcomes (POCOs) defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization were the primary outcome. Stent thrombosis (ST) was the secondary outcome. In both prediabetes and diabetes groups, the cumulative incidences of POCOs, any repeat revascularization, and ST were higher in the 1G-DES than that in the 2G-DES. In the diabetes group, all-cause death and cardiac death rates were higher in the 1G-DES than that in the 2G-DES. In both stent generations, the cumulative incidence of POCOs was similar between the prediabetes and diabetes groups. However, in the 2G-DES group, the cumulative incidences of Re-MI and all-cause death or MI were significantly higher in the diabetes group than that in the prediabetes group. To conclude, 2G-DES was more effective than 1G-DES in reducing the primary and secondary outcomes for both prediabetes and diabetes groups.

scholarly journals Morphological and histopathological study of hypertrophied inferior nasal turbinate in Egyptian patients: in clinical perspective

2020 ◽  
Vol 36 (1) ◽  
Author(s):  
Ashraf Ali El-Demerdash ◽  
Essam Abdel Wanees Beheiry ◽  
Sherif Maher El-Aini ◽  
Asmaa Shams El-Dein Mohamed ◽  
Ahmed Mohamed Ibrahim Khattab
Keyword(s):  
Layer Thickness ◽  
Nasal Septum ◽  
Inferior Turbinate ◽  
Military Hospital ◽  
Deviated Nasal Septum ◽  
Nasal Turbinate ◽  
Egyptian Patients ◽  
Mucosal Layer ◽  
Group A ◽  
Group B

Abstract Background The inferior nasal turbinates have important role in the maintenance of nasal breathing function by providing the nasal valve mechanism necessary for the regulation of air flow through the nose. Hypertrophied inferior nasal turbinates are the second most common cause of chronic nasal obstruction. Our aim of this study is to evaluate the morphological and histopathological features of hypertrophied inferior nasal turbinate in Egyptian patients. Methods Our descriptive comparative study was carried on 30 patients presented with hypertrophied inferior nasal turbinate by clinical and radiological assessment. Patients are divided into two groups according to CT scan and endoscopic examination as group A for patients with deviated nasal septum with compensatory hypertrophied inferior nasal turbinate and group B for patients with hypertrophied inferior nasal turbinate due to allergic rhinosinusitis. Both groups underwent the same operation which partial controlled posterior inferior turbinectomy. During the period from June 2018 till May 2019, patients were selected from out-patient’s clinic of Otorhinolaryngology Department at Menoufia University Hospital and Shebin El-Kom Teaching Hospital, and Military Hospital. Results By histopathological examination of the specimens, we found out that the bony layer thickness was more prominent in group A and the mucosal layer thickness was more prominent in group B. The prominent inflammatory cells were lymphocytes in group A and eosinophils plus mast cells in group B. Conclusion The bony layer thickness should be excised during the surgical treatment of cases presented with deviated nasal septum with hypertrophied inferior turbinate where in cases of allergic rhinitis with hypertrophied inferior turbinate, the mucosal layer is enough to be excised.

scholarly journals A PROSPECTIVE STUDY TO ANALYSE THE SIDE EFFECTS OF OLMESARTAN MEDOXOMIL AND ENALAPRIL IN HYPERTENSIVE SUBJECTS

2018 ◽  
Vol 11 (12) ◽  
pp. 258
Author(s):  
Parminderpal Singh ◽  
Kiranjit Kiranjit
Keyword(s):  
Drug Therapy ◽  
Side Effects ◽  
Postural Hypotension ◽  
Olmesartan Medoxomil ◽  
National Commission ◽  
Group A ◽  
Group B ◽  
Taste Alteration ◽  
A Prospective Study

Objective: The present study was aimed to analyze the side effects of olmesartan medoxomil and enalapril in hypertensive subjects.Methods: The study consisted of newly diagnosed hypertension categorized according to 7th report of Joint National Commission on prevention, detection, evaluation, and treatment of high blood pressure. The subjects were divided into two groups. The Group A subjects received olmesartan, and Group B subjects received enalapril. Pressure was recorded both in supine and sitting positions. The appearance of side effects was observed in the follow-up, i.e., dry cough, headache, postural hypotension, angioedema, dizziness, skin rashes, taste alterations, and urticaria. A statistical data were prepared on the basis of information obtained and analyzed thoroughly for antihypertensive effects and side effects of olmesartan and enalapril. SPSS software was used for analysis.Results: There was observed an increase in the incidence of taste alteration with drug therapy in Group B (Enalapril). There was observed an increase in the incidence of postural hypotension with drug therapy in both groups. In Group A (Olmesartan), the incidence of postural hypotension at the beginning of trial, 4 weeks, and 8 weeks was 0%, 2%, and 2%, respectively. In Group A (Olmesartan), there was no incidence of a headache at the beginning of trial, at 4 weeks and 8 weeks.Conclusion: From the study, it can be concluded that both olmesartan and enalapril are effective in Stage I and Stage II hypertension, but olmesartan is tolerated well with lesser side effects.

scholarly journals Can Co-enzyme Q10 improve the chances of conception after the age of 35?

2017 ◽  
Vol 6 (7) ◽  
pp. 2729
Author(s):  
Eman Ali Abd El Fattah
Keyword(s):  
Chromosomal Abnormalities ◽  
Normal Pregnancy ◽  
Metabolic Energy ◽  
Secondary Outcome ◽  
Slowing Down ◽  
Ovulation Stimulation ◽  
Before And After ◽  
History Of ◽  
Group A ◽  
Group B

Background: ovarian follicular quality diminishes with age, Free radicals and oxidative stress begin to accumulate in cells, aging or slowing down the metabolic energy production centers in the cell- the mitochondria. When the mitochondria cannot generate a certain amount of energy, it slows growth and proper development of the follicle making it more prone to DNA damage, including chromosomal abnormalities resulting in poor fertilization patterns, and early miscarriage. Co-enzyme Q10 (CoQ10) is a major cellular antioxidant. its tissue levels gradually decrease with age. We attempt to evaluate its protective effect on ROS-induced ovarian damage, which is one of the most important and widely accepted patho- mechanisms underlying cell ageing.Methods: 40 Participants   from El Shatby hospital infertility clinic 35 to 38 years old, with history of bad response to ovulation stimulation, were divided into two equal groups (group A given (CoQ10) 3mg|kg body weight for three cycles prior to stimulation Serum anti- mullarian hormone level was measured before and after CoQ10 administration, group B= twenty cases as control). Participants were given gonadotrophins (150 IU to 375 IU). Follicular growth was monitored by trans- vaginal ultra- sonography and serum estradiol level (E2). Ovulation trigger was achieved using 10,000 IU of human chorionic gonadotrophin.Results: The primary outcome was occurrence of normal pregnancy; secondary outcome was good response to stimulation (at least one mature follicle 18-22mm).Conclusions: CoQ10 has no significant effect on response to ovulation stimulation or on pregnancy rates.

Sign in / Sign up

Export Citation Format

Share Document